PCSK9 Inhibitor Drugs Market to Reach 13.0 billion by 2032

PCSK9 Drug Competition Accelerates as Oral, Monthly and Gene-Editing Therapies Expand the Cholesterol-Lowering Landscape

Repatha, Leqvio, Praluent, Lerochol and Lipfendra are creating a broader PCSK9 treatment class as companies compete across efficacy, cardiovascular outcomes, dosing frequency and route of administration.

The PCSK9 drug landscape entered a new stage during 2025 and 2026 as established injectable therapies were joined by a monthly fusion-protein treatment and the first oral PCSK9 inhibitor. Amgen, Novartis, Regeneron, Sanofi, LIB Therapeutics and Merck now compete across monoclonal antibodies, RNA interference, fusion proteins and oral therapy, while AstraZeneca and Eli Lilly are advancing next-generation programs.

Amgen's Repatha (evolocumab) remains the largest commercial product in the class. Repatha sales increased 36% in 2025 to approximately USD 3.0 billion, with Amgen attributing the increase primarily to higher treatment volume. The company also secured a broader U.S. indication in 2025 covering adults at increased risk of major adverse cardiovascular events due to uncontrolled LDL-C, extending use beyond patients with an established cardiovascular disease diagnosis.

Repatha's position is supported by cardiovascular-outcomes evidence in addition to LDL-C lowering. Evolocumab has demonstrated substantial LDL-C reductions in the FOURIER program, while more recent VESALIUS-CV data extended outcomes evidence into high-risk patients without a previous myocardial infarction or stroke. This gives Amgen an established clinical dataset as newer PCSK9 agents enter the market.

Novartis' Leqvio (inclisiran) has developed a distinct position through twice-yearly maintenance dosing. Global Leqvio sales reached USD 1.198 billion in 2025, increasing 59% year over year. Inclisiran uses small interfering RNA to reduce hepatic production of PCSK9 and is administered initially, again at three months, and then every six months.

The next major clinical milestone for Leqvio will be cardiovascular-outcomes data. While its LDL-C lowering profile is established, the ongoing outcomes program remains important for comparison with monoclonal antibodies that already have completed major cardiovascular-event trials.

Praluent (alirocumab) remains another established PCSK9 monoclonal antibody with cardiovascular-outcomes evidence through the ODYSSEY program. Regeneron reported USD 856.8 million in global Praluent sales in 2025, including approximately USD 262.5 million in the United States. Global sales increased 12% compared with 2024. Praluent continues to serve patients requiring additional LDL-C reduction, including patients with established cardiovascular risk and familial hypercholesterolemia.

A new injectable entrant arrived in December 2025, when the FDA approved Lerochol (lerodalcibep-liga) from LIB Therapeutics. Lerochol is a PCSK9-directed recombinant fusion protein administered once monthly. The FDA approval was based on two studies involving 1,844 adults with ASCVD or increased ASCVD risk and another trial involving 478 patients with heterozygous familial hypercholesterolemia. All pivotal studies evaluated treatment on top of existing LDL-C-lowering therapy.

The largest change in treatment format came in July 2026, when the FDA approved Merck's Lipfendra (enlicitide) as the first oral PCSK9 inhibitor. Lipfendra is a 20 mg once-daily tablet approved for adults with hypercholesterolemia, including HeFH. Until this approval, PCSK9-targeted therapies had been administered by injection.

The oral format places Merck in a different competitive position from injectable antibodies and longer-interval RNA-based treatment. Enlicitide has demonstrated LDL-C reductions in the range associated with injectable PCSK9 therapy, making route of administration an increasingly important point of differentiation within the class.

Pipeline competition is also moving quickly. AstraZeneca's AZD0780 is an investigational once-daily oral PCSK9 inhibitor being developed for patients who remain above LDL-C targets despite standard therapy. In the Phase IIb PURSUIT trial, AZD0780 30 mg reduced LDL-C by 50.7% at 12 weeks when added to statin therapy compared with placebo. The program could eventually create direct oral competition within the PCSK9 class if later-stage studies confirm efficacy and safety.

Eli Lilly's VERVE-102 is pursuing a different treatment model. The investigational in-vivo base-editing therapy is designed to durably switch off PCSK9 expression in the liver after a single intravenous administration. In the Phase Ib Heart-2 study, VERVE-102 produced PCSK9 reductions of up to 88% and LDL-C reductions of up to 62%, with effects sustained during follow-up extending to 18 months. Lilly plans Phase II development.

These programs create an increasingly diverse competitive field. Amgen and Regeneron/Sanofi have established monoclonal antibodies with cardiovascular-outcomes evidence; Novartis competes through long-interval siRNA dosing; LIB Therapeutics has added monthly fusion-protein therapy; Merck has established the first oral PCSK9 option; AstraZeneca is advancing another oral candidate; and Lilly is testing whether PCSK9 suppression can eventually be delivered through one-time gene editing.

The next phase of PCSK9 competition will therefore be shaped by LDL-C reduction, cardiovascular outcomes, dosing frequency, administration route, safety, treatment persistence and payer access. The class has expanded from a small group of injectable antibodies into a broader cardiovascular-drug category with oral, RNA-based, fusion-protein and gene-editing approaches now competing for clinical relevance.